You are currently browsing the archives for 25 March 2018.
Displaying 1 entry.

Clinical Data reports $2.

THE BUSINESS did not have any revenue through the three months ended December 31, 2009, after the financial statements were modified to reflect the genetic and biomarker advancement business as discontinued functions. Research and development expenses were essentially smooth at $8.9 million for the three months ended December 31, 2010, weighed against $8.december 31 8 million for the three months ended, 2009. Research and development efforts were primarily due to the commercialization actions for Viibryd in anticipation of FDA acceptance, which happened in early 2011, and the ongoing Phase III ASPECT 1 trial for Stedivaze.